Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Journal for immunotherapy of cancer（2023）
摘要
JapicCTI-194782, jRCT2080224706, UMIN000036970.
更多查看译文
关键词
breast cancer,nivolumab,endocrine therapy,abemaciclib,hr-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要